{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T14:39:46Z","timestamp":1649083186088},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.cld.2009.05.005","type":"journal-article","created":{"date-parts":[[2009,7,22]],"date-time":"2009-07-22T05:19:43Z","timestamp":1248239983000},"page":"365-373","source":"Crossref","is-referenced-by-count":1,"title":["Antifibrotics for Chronic Hepatitis C"],"prefix":"10.1016","volume":"13","author":[{"given":"Paul J.","family":"Pockros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6B","key":"10.1016\/j.cld.2009.05.005_bib1","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/S0002-9343(99)00377-0","article-title":"Evaluation of fibrosis and hepatitis C","volume":"107","author":"Friedman","year":"1999","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.cld.2009.05.005_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/jhep.2000.9109","article-title":"Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats","volume":"32","author":"Nakamura","year":"2000","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.cld.2009.05.005_bib3","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","article-title":"Transforming growth factor beta in tissue fibrosis","volume":"331","author":"Border","year":"1994","journal-title":"N Engl J Med"},{"issue":"6721","key":"10.1016\/j.cld.2009.05.005_bib4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/17826","article-title":"Inhibition of transforming growth factor-beta\/SMAD signalling by the interferon-gamma\/STAT pathway","volume":"397","author":"Ulloa","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.cld.2009.05.005_bib5","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury","volume":"275","author":"Friedman","year":"2000","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.cld.2009.05.005_bib6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJM199910213411703","article-title":"A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis","volume":"341","author":"Ziesche","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2009.05.005_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hep.1840130220","article-title":"High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial","volume":"13","author":"Saez-Royuela","year":"1991","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2009.05.005_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hep.21561","article-title":"Final results of a double-blind, placebo-controlled trial of the anti-fibrotic efficacy of interferon-gamma 1b in chronic hepatitis C with advanced fibrosis or cirrhosis","volume":"45","author":"Pockros","year":"2007","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2009.05.005_bib9","doi-asserted-by":"crossref","first-page":"A 718","DOI":"10.1016\/S0016-5085(03)83626-0","article-title":"Interferon gamma-1 for the treatment of chronic hepatitis C infection","volume":"124","author":"Muir","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2009.05.005_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2005.02.023","article-title":"Pilot study of interferon gamma for chronic hepatitis C","volume":"43","author":"Soza","year":"2005","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2009.05.005_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hep.1840110217","article-title":"Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon","volume":"11","author":"Di Bisceglie","year":"1990","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2009.05.005_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jmv.1890350108","article-title":"Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon","volume":"35","author":"Kakumu","year":"1991","journal-title":"J Med Virol"},{"issue":"8","key":"10.1016\/j.cld.2009.05.005_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1542-3565(05)00404-0","article-title":"Effect of interferon gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study","volume":"3","author":"Weng","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2009.05.005_bib14","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.21595","article-title":"Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis","volume":"45","author":"Goodman","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2009.05.005_bib15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.cgh.2006.07.006","article-title":"Fibrosis as an end point for clinical trials in liver disease: a consensus report of the International Fibrosis Group","volume":"4","author":"McHutchison","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"23","key":"10.1016\/j.cld.2009.05.005_bib16","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2009.05.005_bib17","first-page":"238A","article-title":"High early viral response (EVR) with PEG-Intron\/Rebetol (PR) weight based dosing (WBD) in previous interferon\/ribavirin HCV treatment failures; early results of the EPIC3 trial","volume":"40","author":"Poynard","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2009.05.005_bib18","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1053\/j.gastro.2009.01.039","article-title":"Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa\/ribavirin therapy","volume":"136","author":"Poynard","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2009.05.005_bib19","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(08)60005-7","article-title":"Colchicine versus peg-interferon alfa 2B long term therapy: results of the 4 year copilot trial","volume":"48","author":"Afdhal","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2009.05.005_bib20","first-page":"239A","article-title":"Colchicine versus PEG-Intron long term (COPILOT) trial: interim analysis of clinical outcomes at year 2","volume":"40","author":"Afdhal","year":"2004","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2009.05.005_bib21","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S0168-8278(08)60146-4","article-title":"Suppression of serum HCV RNA levels during maintenance peginterferon (PEG-IFN) alfa-2a therapy and clinical outcomes in the HALT-C trial","volume":"48","author":"Shiffman","year":"2008","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2009.05.005_bib22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gut.2004.053850","article-title":"Apoptosis: a mechanism of acute and chronic liver injury","volume":"54","author":"Guicciardi","year":"2005","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2009.05.005_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.cld.2009.05.005_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.20051","article-title":"Apoptosis: the nexus of liver injury and fibrosis","volume":"39","author":"Canbay","year":"2004","journal-title":"Hepatology"},{"issue":"4 Pt 1","key":"10.1016\/j.cld.2009.05.005_bib25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/jhep.2001.28229","article-title":"Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection","volume":"34","author":"Bantel","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2009.05.005_bib26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1046\/j.1365-2893.2001.00316.x","article-title":"Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection","volume":"8","author":"Pianko","year":"2001","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.cld.2009.05.005_bib27","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1124\/jpet.103.062034","article-title":"Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor","volume":"309","author":"Hoglen","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.cld.2009.05.005_bib28","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1124\/jpet.103.060129","article-title":"The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse","volume":"308","author":"Canbay","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.cld.2009.05.005_bib29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hep.21664","article-title":"Oral IDN-6556, an antiapoptotic caspase inhibitor, lowers aminotransferases in patients with chronic hepatitis C","volume":"46","author":"Pockros","year":"2007","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326109000312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326109000312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T02:25:31Z","timestamp":1545099931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326109000312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1089326109000312"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2009.05.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}